General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. At a Glance
Growth came roaring back. FY26 revenue hit ₹1,769 Cr, up 31% from ₹1,346 Cr in FY25—a sharp rebound from FY24’s slide. Net profit climbed to ₹74.34 Cr, marking a 22.6% climb.
But margins stayed flat. Operating profit margin: 5.1% in FY26, unchanged from FY25. PAT margin inched from 4.5% to 4.2%—a small compression, not a widening. The stock has tanked 39.6% in the past three months, and earlier this month, the exchange sought a clarification on the price movement. No undisclosed event was found. The company then surprised with a 2:1 bonus in December 2025 and a warrant conversion in February 2026.
The tension: revenue scales, but profitability doesn’t. Domestic sales are now 41% of the mix (up from 23% in FY24), yet margin lift isn’t visible. Is this a transition play or a stall?
2. Introduction
GRM Overseas was incorporated in 1995 as an offshoot of the Garg family’s rice milling legacy, which traces back to 1974 as Garg Rice & General Mills. The company sits on a production capacity of roughly 440,800 MT per annum (Panipat, Haryana) and another 110,000 MT through Naultha and Gandhidham, with 9 sortex plants holding an additional 1,400 MT per day cleaning capacity.
The core export game has been rice to the Middle East and Europe—40+ countries, 200+ international distributors. Retail tie-ups include ASDA Walmart (UK), Carrefour (UAE), Tesco (UK), and a roster of regional players. Domestically, after years of playing small, the 10X brand (launched through subsidiary GRM Foodkraft Pvt Ltd) is now a material driver—spices, atta, ready-to-eat biryani kits, and the newly added mustard oil under 10X Shakti (launched July 2024).
In August 2024, management announced 10X Ventures: a ₹200 Cr digital-first rollup play targeting D2C brands and lifestyle categories, aiming to turn the rice business into a “blended house of brands” with traditional FMCG discipline and e-commerce agility. The company also expanded its Diplomat Georgia tie-up to place Tanoush basmati rice into Eastern European distribution. Promoter holding has slipped from 72% in mid-2025 to 62.5% after warrant conversions and bonus dilution, while FIIs have crept in to 9.5%.
3. Business Model: WTF Do They Even Do?
The playbook is old, the execution uneven.
Exports (59% of FY26 revenue, ₹1,044 Cr). Basmati rice—premium grades like Himalaya River (blue, jumbo, sella, brown) and Tanoush (organic, 1121 emperor, 1401 king)—goes in bulk to foreign retailers and distributors. The company buys paddy seasonal, mills, sorts, packages, and ships. Volumes recovered: Q4 FY26 showed ₹597 Cr sales, a 105% leap from Q4 FY25 (₹291 Cr). That kind of swing is either real or inventory release; the data doesn’t scream manipulation, but caution is apt.
Domestic Retail (41% of FY26, ₹725 Cr). The 10X brand—”essential consumer goods, kitchen necessities”—is now the second leg. Rice, spices, atta, ready-to-eat and instant offerings. 103,545 kirana touchpoints tracked in the system (as of last published). Flipkart, BigBasket, Meesho, Amazon, Zomato for modern trade; JioMart, Udaan, Elasticurn for general trade. A mustard oil launch in July 2024 suggests category creep—margin expansion, or just broader SKU clutter?
The risk. Exports are weather-dependent (paddy yields), FX-exposed (revenues in dollars, costs partly in rupees), and hostage to global demand shifts. The recent domestic push into branded retail is a margin play but requires scale and advertising—capital-heavy, slow to compound. Management is hedging with 10X Ventures, but that’s a separate venture whose returns are years out.
Capacity utilization remains opaque. With 550 MT/day milling and 1,400 MT/day sorting, the group can theoretically handle 2+ lakh MT annually; FY26 sales of ₹1,769 Cr likely represent 1.3–1.5 lakh MT at blended prices (~₹1,200/MT), so the mills are running, not idling.
4. Financials Overview
Figures are consolidated, in ₹ crore.
| Metric | FY26 | FY25 | YoY Change | FY24 | YoY Change |
|---|---|---|---|---|---|
| Revenue | 1,769 | 1,347 | +31.4% | 1,312 | +2.6% |
| EBITDA | 127 | 107 | +18.7% | 100 | +6.5% |
| PAT | 74.3 | 60.6 | +22.6% | 59.8 | +1.3% |
| EPS (Annualised FY) | 3.59 | 3.37 | +6.5% | 3.32 | +1.5% |
Key Movements:
Q4 FY26 (Jan-Mar 2026) on its own: Revenue ₹597 Cr (up 105% QoQ from Q3’s ₹362 Cr), net profit ₹21.61 Cr (EPS ₹1.04 annualised = 4 × Q4 × (1/4) of year… no, wait—Q4 is the final quarter of the fiscal year. Full FY EPS is ₹3.59, so use that as the reported EPS). Operating profit margin in Q4: 5.0% (₹30 Cr ÷ ₹597 Cr). PAT margin: 3.6%.
The surge in Q4 is the headline. Months of tepid volumes (Q2: ₹327 Cr, Q3: ₹362 Cr) suddenly compressed into a final-quarter export dash. Whether this is real demand realization or year-end inventory shifting isn’t clear from the numbers alone. The credit rating agency noted “improvement in the scale of operations in 9MFY2025 post a marginal decline in FY2024.”
5. Market Expectations & Historical Multiples
This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.
| Metric | Current | Historical Avg (5 Yr) | Peer Median |
|---|---|---|---|
| P/E | 26.1x | 25.5x | 16.6x |
| EV/EBITDA | 17.6x | — | — |
| ROE | 14.5% | 21.3% | 14.5% |
| ROCE | 14.0% | — | 14.2% |
| P/B | 3.21x | — | 2.18x |
The market currently pays 26.1x earnings here versus a peer median of 16.6x. The multiple sits above the company’s own 5-year average of 25.5x, suggesting current sentiment is in line with historical peaks, not discounting.
Return on Equity stands at 14.5%—healthy against the peer set median of 14.5% but well below the company’s own 5-year average of 21.3%, signalling diminished capital efficiency. ROCE mirrors that: 14.0% now, peer median 14.2%. The business is no longer a high-return outlier.
What is the market pricing in? The domestic expansion (41% of revenue, growing) is betting on scale in 10X; the export recovery (Q4’s surge) is betting on demand normalization post global slowdown; the 10X Ventures rollup (₹200 Cr committed) is betting on FMCG roll-up economics, which have worked for others but carry operational risk. The multiple sits flat despite margin compression and ROE decline, suggesting the market is either already pessimistic or waiting for the domestic/venture thesis to crystallize.
6. What’s Cooking
Warrant conversion push. In August 2024, management issued 90.7 lakh convertible warrants at ₹150 (₹37.5 warrant price upfront). By February 2026, 77.18 lakh had converted, raising equity and diluting shares. This capital infusion—₹86.82 Cr received by February, with ₹136.05 Cr expected if all were to convert—is meant for 10X Ventures rollups. The promoter stake dropped from 72% to 62.5% in the process.
Bonus issue (2:1 in December 2025). A 2:1 bonus (12.27 Cr shares allotted, record date Dec 24, 2025) doubled the share count and halved the face value–adjusted EPS. This is typically a sign of excess capitalization or a signal to retail—or both. Post-bonus, shares outstanding moved from ~20.7 Cr to ~41.4 Cr.
10X Ventures operational ramp. In August 2024, GRM signed an MoU with Harvesting India Foundation to place products on their virtual platform and Kisan Centres. HFN procured 20,000 MT paddy, 12,000 MT wheat, 5,000 MT mustard for GRM in FY23. The domestic mix went from 23% (FY23) to 41% (FY26)—the rollup is gaining traction.
Mustard oil and category expansion. July 2024 launch of Gulistan Kachi Ghani Mustard Oil under 10X Shakti suggests margin accretion play, but no revenue breakout visible yet.
Credit rating upgrade and affirmation. In November 2023, Acuité upgraded GRM to ACUITE A- / Stable and A2+ short-term, citing “healthy financial risk profile” and “improvement in revenues in 9MFY2025.” April 2025 reaffirmed. The rating remains constrained by working capital intensity and agro-climatic exposure, but the agency sees “healthy net cash accruals of ₹64.39 Cr in FY2024 against minimal maturing debt.”
Diplomat Georgia distribution tie-up (July 2024). Agreement to place Tanoush basmati rice through DIPLOMAT’s channels in Eastern Europe signals geographic expansion beyond the traditional Middle East–US–UK corridor.
Exchange clarification (June 2026). On June 10, 2026, BSE sought clarification on the stock’s sharp price drop (39.6% in three months). Company clarified no material event or undisclosed information was behind it. The announcement came the same week as the Q1 FY27 results trajectory became evident—no change, no news, just drift.
7. Balance Sheet
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Total Assets | 770 | 911 | 1,160 |
| Total Liabilities | 770 | 911 | 1,160 |
| Net Worth (Equity + Reserves) | 425 | 426 | 602 |
| Borrowings | 393 | 364 | 368 |
| Other Liabilities | 46 | 121 | 191 |
Assets = Liabilities. ✓
The three observations:
- Net worth jumped 41% (FY26). Reserves climbed from ₹414 Cr to ₹560 Cr (+35%). Equity capital nearly quadrupled (₹12 Cr to ₹41.44 Cr) due to bonus and warrant conversions. The balance sheet got fatter on paper; the underlying earning power didn’t scale at the same pace.
- Borrowings stayed nearly flat. ₹368 Cr in FY26 vs. ₹364 Cr in FY25 vs. ₹393 Cr in FY24. No new debt issuance; the company is funding growth via warrant proceeds and internal cash. That’s prudent but also suggests capex is light or non-existent.
- Other Liabilities surged 58% (FY26). From ₹121 Cr (FY25) to ₹191 Cr (FY26). No clarity on composition from the data—could be payables, accrued expenses, deferred revenue, or earnout liabilities tied to 10X Ventures acquisitions. A red flag to investigate in the annual report.
Wisdom: A balance sheet with 3.2x book value and flat borrowings tells you growth is coming from operational leverage or M&A, not balance sheet stretch. But the ₹191 Cr “other liabilities” is a fog; it hides either operational nuance or integration debt.
Net Cash Position: Cash & Bank climbed from ₹52.83 Cr (FY25) to ₹73.53 Cr (FY26). After borrowings, net cash is roughly ₹(368 − 73.53) = ₹294.47 Cr debt, or about 0.49x Net Worth. Healthy gearing.
8. Cash Flow: Sab Number Game Hai
| Year | Operating | Investing | Financing |
|---|---|---|---|
| FY24 | 47 | -4 | -39 |
| FY25 | 62 | -8 | -12 |
| FY26 | -54 | -53 | 82 |
FY26 tells the story: operating cash flow turned negative (−₹54 Cr). Working capital chewed up ₹116 Cr year-on-year (FY25 saw +₹62 Cr from operations). Investing activity burned ₹53 Cr (likely capex on 10X Ventures or facility upgrades). Financing activity brought in ₹82 Cr (warrant conversions and possibly term loans).
The translation: The company reported ₹74.3 Cr net profit but burned ₹54 Cr in cash from operations. Where’s the gap? Receivables and inventory expansion. Debtor days ballooned from 130 (FY25) to 119 (FY26)—wait, that’s an improvement. Inventory days: 102 (FY25) to 104 (FY26)—flat. So the cash burn came from building working capital for the Q4 revenue surge: pre-positioning inventory, advancing supplier payments, or extending credit to new retail partners.
Free cash flow (Operating − Investing): −₹107 Cr in FY26. Negative FCF while reporting positive earnings is a red flag for working capital intensity and/or acquisition drag. The company is funding growth via external capital (warrant proceeds), not internal generation.
Wisdom: Cash burn with profit growth is the signature of a working-capital machine under growth stress. Rice export and domestic retail expansion both tie up cash—paddy procurement, forward inventory, extended trade credit to distributors. The business model expects this, but it means the company needs external funding or operating leverage to emerge at the other end. The warrant conversion is designed to foot that bill.
9. Ratios: Sexy or Stressy?
| Ratio | FY26 | FY25 | 5-Yr Avg |
|---|---|---|---|
| ROE | 14.5% | 14.5% | 21.3% |
| ROCE | 14.0% | 14.0% | — |
| P/E | 26.1x | — | 25.5x |
| PAT Margin | 4.2% | 4.5% | — |
| Debt-to-Equity | 0.61x | 0.85x | — |
Return on Equity is 14.5%—the company is earning 14.5 paise per rupee of shareholder capital. Five years ago, it was 21.3%. The equity base expanded (bonus, warrants), but the earnings didn’t scale proportionally. This is dilution without growth.
ROCE mirrors the problem: 14.0%, flat year-over-year. Against a 14.2% peer median, the company is no longer delivering excess returns on its capital. Capital employed expanded (via bonus and warrant dilution), but returns didn’t.
P/E at 26.1x is expensive for a business with flattening margins and ROE trending down. The peer median is 16.6x.
PAT Margin compressed from 4.5% to 4.2%—minor, but directionally wrong given the revenue surge.
Debt-to-Equity improved from 0.85x to 0.61x thanks to equity dilution, not debt reduction. Mechanical, not operational.
The signal: The company is levering balance-sheet engineering (dilution) over operational improvement (margin expansion). ROE and ROCE are healthy, not exceptional, and they’re not expanding. A business that grows revenue 31% but can’t grow return on capital is one where growth is being funded via dilution, not profitability.
10. P&L Breakdown: Show Me the Money
| Year | Revenue | EBITDA | PAT |
|---|---|---|---|
| FY24 | 1,312 | 100 | 60 |
| FY25 | 1,347 | 107 | 61 |
| FY26 | 1,769 | 127 | 74 |
Revenue recovered sharply in FY26 after two years of flatness. EBITDA inched up 19% (from ₹107 Cr to ₹127 Cr)—decent, but operating leverage is muted (revenue +31%, EBITDA +19%). That suggests either:
- Raw material inflation eating into gross margin (paddy/rice costs), or
- Distribution/freight costs rising faster than volume (export surge), or
- Domestic expansion requiring heavier discounting or promotional spend.
PAT grew 22.6%, faster than EBITDA (due to lower interest expense: ₹23 Cr in FY26 vs. ₹18 Cr in FY25, offset by higher tax). But the margin story is one of stalling: operating profit margin 5.1% (stable), PAT margin 4.2% (down from 4.5%).
The three-year trajectory: Revenue bounced around ₹1,300–1,380 Cr for two years, then FY26 kicked it to ₹1,769 Cr. PAT stayed in the ₹60 Cr zone for two years, then FY26 hit ₹74.34 Cr. The move is real, but margins are not expanding with it.
Question: Can the domestic push (now 41% of revenue) deliver 8–10% PAT margins, or will it stabilize at export-level 4–5%?
11. Peer Comparison
| Company | Revenue (FY) | PAT (FY) | P/E | ROE | OPM |
|---|---|---|---|---|---|
| LT Foods | 10,946 | 625 | 21.2x | 14.9% | 10.6% |
| KRBL | 6,098 | 648 | 12.9x | 11.7% | 14.8% |
| Guj. Ambuja Exp | 5,729 | 307 | 23.6x | 9.8% | 8.1% |
| Kaveri Seed Co. | 1,395 | 296 | 15.3x | 18.2% | 24.2% |
| Sanstar | 785 | 34 | 61.8x | 5.1% | 4.8% |
| GRM Overseas | 1,769 | 74 | 26.1x | 14.5% | 5.1% |
| Peer Median | 546 | 24 | 16.6x | 14.5% | 10.1% |
GRM pays the second-highest multiple (26.1x) after Sanstar (outlier), on revenue that’s 3x the median but a fraction of LT Foods’ scale. KRBL is half the price (12.9x) on 3.4x higher PAT. LT Foods pays 21.2x for 8.4x the profit and 6.2x the revenue—that’s scale arbitrage.
Operating margin: GRM’s 5.1% is below the peer set (median 10.1%), below KRBL (14.8%), below LT Foods (10.6%). Only Sanstar is worse. GRM is large-scale but low-margin, and the market is pricing it as if that’s going to change.
The peer story: rice exporters and FMCG players have wide margin spreads (KRBL’s 14.8% OPM, Kaveri’s 24.2%). GRM’s 5.1% is the low end, yet it trades at the high end of the P/E range. That’s a bet on expansion that hasn’t happened yet.
12. Miscellaneous: Shareholding & Promoters
| Holder | % (FY26) | % (FY25) | Change |
|---|---|---|---|
| Promoters | 62.51% | 72.43% | -9.92 pp |
| FIIs | 9.50% | 0.72% | +8.78 pp |
| DIIs | 2.91% | 0.25% | +2.66 pp |
| Public | 25.08% | 26.59% | -1.51 pp |
The shift: Warrant conversions and bonus dilution handed retail and foreign investors a larger piece. FIIs have gone from nothing (0.72%) to meaningful (9.50%) in 12 months—Forbes EMF (2.90%), Coeus Global Opportunities (2.90%), Samsung India Securities (1.02%). Promoters went from 72.4% to 62.5%, a 9.9 percentage-point slide.
Promoter bios: Hukam Chand Garg (21.88% as of March 2026, down from 25.01% in mid-2023) founded the rice business in 1974 as Garg Rice & General Mills. His son Atul Garg (20.51%, down from 23.95%) now heads operations. Mamta Garg (20.12%) and Reena Jain held stakes but appear diluted post-warrant conversion.
The roast: Promoter dilution in a family business is usually a capital-raising move (which it is—warrant conversions for 10X Ventures), but it also signals a pivot from founder control to institutional oversight. The FII inflow suggests confidence in the growth thesis, or at least confidence in the valuation reset. The speed of the FII entry (9.5% in a quarter) suggests momentum trading, not conviction.
13. Corporate Governance: Angels or Devils?
Auditors: Not specified in the data, but typically Big 4 for a listed entity this size.
Board & Management: Hukam Chand Garg (founder), Atul Garg (CEO, his son), Mamta Garg, and newer appointees like Sumit Mittal (appointed Nov 2025) and departures like Raj Garg (resigned Nov 2025). A small, family-led board with recent institutional additions.
Pledges: Zero pledged shares as of March 2026—no promoter collateral against loans. That’s clean.
Related-party transactions: The AGM on Sep 29, 2025 approved material RPTs up to ₹750 Cr and borrowing limits up to ₹600 Cr. No detail on specific transactions, but the quantum is material.
Resignations: Raj Garg’s resignation in November 2025 and appointment of Sumit Mittal in the same breath suggests a board refresh, possibly to bring independent/institutional credibility ahead of the 10X Ventures expansion or future funding rounds.
Tax demands: No mention of open tax disputes in the filings reviewed. The Acuité rating report (April 2025) does not flag tax risk.
Credit rating: Acuité A- (Long-term) / A2+ (Short-term) with Stable outlook as of April 2025. Reaffirmed. No downgrades, no flags beyond the inherent working-capital and agro-climatic risks already noted.
Red flags as facts: The ₹191 Cr “other liabilities” surge (58% YoY) is not explained; it could be contingent earnout payments to 10X Ventures targets or integration accruals. The negative FCF while reporting positive earnings is typical for working-capital-intensive businesses, but it means the company is structurally dependent on external funding or margin expansion to self-fund. Neither has materialized yet.
14. Industry Roast & Macro Context
The rice export market is being hollowed out.
India exports basmati at a premium to long-grain varieties, but global demand is cyclical: Middle Eastern consumption of premium basmati is inelastic (weddings, restaurants, wealthy households), but it’s not a growth category. Europe is finicky about price and certification. The US market is small and competitive. When global commodity prices spike (as they did in 2022–2023), exporters’ margins compress unless they can hike prices faster than paddy costs rise. GRM’s 5.1% OPM suggests they’re not doing that.
Domestically, the 10X brand competes in a screaming-loud FMCG space: Aashirvaad (ITC), Basmati 1121 (various), Daawat (private), Himalaya (GRM’s own premium label), and a hundred regional and private-label players. To win, brands either go mass-market (tight margins) or premium (scale challenge). The 10X brand has chosen mass (103,545+ kirana stores)—margin compression is likely.
Pricing power is eroding. Basmati hit ₹4,500/MT export prices in 2022; it’s now ~₹2,500–3,000/MT depending on grade. GRM’s blended export realization is opaque, but if it’s in the ₹2,500–2,700/MT range for 9-month averages in FY26, then the margin story is one of volume recovery, not pricing recovery.
Agro-climatic risk is real. Paddy is a monsoon crop; a weak monsoon kills supply and shoots prices up (bad for millers’ margins if paddy prices spike faster than rice prices). A strong monsoon floods supply and crashes prices (bad for paddy farmers, but GRM can buy cheap, though that’s a one-time bump). The 2024 monsoon in the rice-growing regions (Punjab, Haryana, Uttar Pradesh) was normal to surplus, so FY26’s volume recovery was likely real, not a lucky price play.
Regulation: The government has periodically restricted rice exports (2022–2023 saw caps on basmati export volumes). No active curbs as of June 2026, but the risk remains political. A sudden export tax or quota cut would crater volumes and cash flow.
Macro tailwind for domestic FMCG: The 10X brand’s growth (41% of revenue) is riding the wave of rural-to-urban income growth and modern trade penetration. That’s real. But it requires reinvestment in distribution and marketing—capex that GRM is funding via warrant proceeds, not FCF. Whether that converts to margin expansion is the open question.
15. EduInvesting Verdict
| Strengths | Weaknesses |
|---|---|
| Revenue rebounded 31% in FY26 after two years of stalling. Market position as 3rd-largest rice exporter in India. Expanded domestic presence to 41% of revenue via the 10X brand. Zero pledged shares and low debt-to-equity (0.61x). Acuité A- rated, stable outlook. | Operating margins flat (5.1%) despite 31% revenue growth. ROE and ROCE stuck at 14%, down from 5-year avg of 21%. P/E of 26.1x sits above peers (16.6x median) despite lower margins. Negative FCF (−₹107 Cr) while reporting positive earnings. Working-capital intensity and seasonal cash flow volatility. |
| Opportunities | Threats |
| 10X Ventures rollup (₹200 Cr capex planned) targeting D2C brands and category expansion (mustard oil, atta). Geographic expansion (Diplomat Georgia tie-up, 50+ export countries). Domestic retail scale (103,545 kiranas) offers margin re-rating potential if private label shifts to owned brands. Warrant conversions and bonus provide capital for M&A. | Global basmati demand cyclical; export realization under pressure (₹2,500–3,000/MT vs. ₹4,500/MT in 2022). Agro-climatic exposure (monsoon-dependent paddy supply) and foreign exchange volatility. Domestic 10X expansion is margin-dilutive until scale (likely 3–5 years out). Promoter dilution (62.5% vs. 72% a year ago) signals control loss and potential governance drift. ₹191 Cr “other liabilities” surge unexplained. |
The central tension: A rice exporter with a domestic pivot, trading at premium multiples because the domestic pivot is supposed to unlock 8–10% margins. But the company has yet to prove it can grow revenue 31% and expand margins. FY26 showed it can do the first; FY27–FY28 will tell if it can do the second.
A balance sheet with nothing to hide, a multiple with everything to prove.